Development Of Minimal Residual Disease (MRD) Analysis In Childhood Acute Lymphoblastic Leukaemia (ALL) By Next Generation Sequencing (NGS)

Helen Williamson, Edward Mountjoy, Hashem Shihab, Jack Bartram, Mike Hubank, Nicholas Goulden, Ian Day, Eileen Roberts, John Moppett, Jeremy Hancock

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

Detection of sub-microscopic levels of disease (minimal residual disease; MRD) in childhood acute lymphoblastic leukaemia (ALL) during treatment is an important prognostic factor. Currently, stratification of therapy for the new frontline trial in childhood ALL (UKALL 2011) is provided by MRD analysis using real time quantitative PCR (RQ-PCR) to identify and quantitate the patient specific rearrangements of the immunoglobulin (Ig) and T-cell receptor (TCR) genes. The current methodology is expensive, time-consuming and complex to perform. Although MRD has proven to be a powerful and essential tool in stratification of ALL patients, 8% of individuals in the current UKALL 2011 trial do not have an informative MRD result. Recently, Next Generation Sequencing (NGS) has led to the opportunity to improve the sensitivity and specificity of Ig/TCR based MRD analysis. In this study, we focussed on the IgH locus using BIOMED 2 primers (van Dongen et al., 2003) modified to allow target identification and quantitation by deep sequencing on the Illumina MiSeq platform. We developed a novel pipeline to automate the clustering and classification of sequencing reads leading to characterisation of the clonal subtypes present. In a sample of 12 patients, the method correctly identified all the major clones revealed by current methodologies, and also detected many related and unrelated low-frequency clones. Additional targets were also identified in patients in which no IgH targets were detectable by current methodologies. These NGS-identified targets were subsequently used to monitor MRD by RQ-PCR to the desired quantitative range required for stratification of therapy according to UKALL 2011 guidelines ([Figure 1][1]). In addition, we were able to delineate patterns of IgH rearrangements in two patients previously shown to have oligoclonal (textgreater2) rearrangements. Such patients represent a time consuming and technical challenge for current technologies as it is important that all targets at the locus are followed by RQ-PCR to provide an informative and robust MRD result. Furthermore, by clustering similar sequences, we identified diagnostic samples where multiple V regions are attached to the same N1-D-N2-J region. This may allow for the study of clonal evolution in follow-up samples. Altogether, NGS sequencing has the potential to significantly reduce false negative results, as multiple evolved clones can be identified. This methodology also represents a significant time saving (5-7 days) in comparison to established methods (3-4 weeks). ![Figure 1.][2]textless/imgtextgreater Figure 1. (a) Polyacrylamide electrophoresis could not recognise a target to use in current MRD methodologies (well 1 containing the products from a PCR reaction that would amplify VH1 and VH7, and wells 2-6 amplifying VH2-6, respectively), while the NGS pipeline could identify a VH7 rearrangement (b). (c) ASOs were designed to amplify the NGS-identified VH7-81*01 DH3-9*01 JH4*02 rearrangement and optimised to correctly identify 10-2, 10-3, 10-4 dilutions with a single NAC (non-amplification control; monocytes from 20 normal individuals) replicate amplified, therefore meeting current guidelines for a MRD target. Having established NGS for identifying clonal targets in ALL, we are currently assessing the ability of the method and pipeline to quantify disease levels in end of induction and relapse samples, previously analysed by RQ-PCR, to determine the concordance between the methodologies. Indeed, logarithmic dilution series of patient DNA in a normal background revealed that stratification based on a clinical threshold of 1 in 1,000,000 is possible using this methodology. Further investigation into the clinical utility of NGS for MRD analysis will focus on analysing earlier time points in treatment and studying the potential use of blood rather than bone marrow. Altogether, this will further improve the predictive value and specificity of MRD testing. Disclosures: No relevant conflicts of interest to declare. [1]: F1 [2]: pending:yes
Original languageEnglish
Pages (from-to)2569-2569
Number of pages1
JournalBlood
Volume122
Issue number21
Early online date5 Dec 2013
Publication statusPublished - 2013

Fingerprint Dive into the research topics of 'Development Of Minimal Residual Disease (MRD) Analysis In Childhood Acute Lymphoblastic Leukaemia (ALL) By Next Generation Sequencing (NGS)'. Together they form a unique fingerprint.

Cite this